Eaton Vance Management Vericel Corp Transaction History

Eaton Vance Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$31.69 - $43.29 $136,710 - $186,753	-4,314 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$35.2 - $52.6 $2,921 - $4,365	83 Added 1.96%	4,314 $157,000
Q3 2021 Nov 15, 2021	SELL	$46.35 - $59.75 $14,507 - $18,701	-313 Reduced 6.89%	4,231 $195,000
Q2 2021 Aug 16, 2021	SELL	$47.2 - $67.81 $30,302 - $43,534	-642 Reduced 12.38%	4,544 $238,000
Q1 2021 May 17, 2021	BUY	$30.93 - $59.48 $160,402 - $308,463	5,186 New	5,186 $288,000

276

48.8M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.7B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

Stay updated on Eaton Vance Management with notifications on news.